Exonbio has developed SARS-CoV-2 Spike recombinant monoclonal antibodies for the global IVD and research communities in support of efforts to combat the pandemic. By using Exonbio’s SPIN® technology platform, highly specific antibodies from plasma cells are generated against spike protein of SARS-CoV-2. These high affinity and sensitivity antibodies can be used for antigen detection of diagnostic kit development.
SARS-CoV-2 Spike S1 protein IgG mAbs
|Clone ID||Isotype||Species||EC50 (ng/ml)|
Please reach out to us at firstname.lastname@example.org for more information about our SARS-CoV-2 Spike S1 protein monoclonal antibodies.
High-affinity monoclonal antibodies that fall in different epitope bins allow for antibody pairing for the development of ELISA kit. For detailed Spike monoclonal pairing & clone information contact us.
ELISA: Spike S1 protein IgG mAbs are high affinity, with EC50 range between 2.1-7.2 ng/ml.
Neutralization Assay: The S1-targeting monoclonal antibodies blocks the interaction between receptor binding domain and ACE2 receptor and exhibits high levels of neutralization activity.